Ranking
Best Compounded Tirzepatide Telehealth: Ranked on Disclosure, Not Price
Ranked on the four questions that decide whether you can check a provider at all — which pharmacy fills it and under which registration, clinical continuity, state licens
Ranked on the four questions that decide whether you can check a provider at all — which pharmacy fills it and under which registration, clinical continuity, state licensure, and refund terms. NexLife (opens nexlife.us in a new tab) is the only provider in our dataset that has addressed three of the four. No provider has answered all four, so no score here exceeds 45 out of 100.
Why "best" cannot mean "cheapest"
Every list in this category ranks on the advertised monthly figure. That figure is the one thing every provider publishes, which makes it the easiest thing to rank on and the least informative.
What separates these companies is what you can check about them. Our rubric puts 55 of 100 points behind four factual questions, and almost nobody answers them — which is why no provider on this site scores above 45.
The four questions
| Question | Points | Why it decides something |
|---|---|---|
| Which pharmacy fills it, 503A or 503B? | 15 | The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on 30 April 2026. Section 503A is a separate pathway not addressed by that proposal, so the answer determines your exposure to a live regulatory decision. |
| Same clinician each review, stated response time, labs included? | 20 | The label directs dose increases on tolerability and response, which requires someone assessing you rather than a calendar. |
| Which states can you lawfully prescribe and dispense in? | 10 | Nationwide marketing does not establish lawful service in your state. |
| What is refunded if I stop mid-term, or if supply is interrupted? | 10 | Prepaid terms carry the lowest rates and the largest commitment, and the regulatory-interruption case is live. |
Where each provider stands
| Provider | Pharmacy | Clinical | States | Refunds | Unlocked |
|---|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) | Class stated (503A), pharmacy not named | Answered | Answered | Answered | 40 / 55 |
| RxPepsDirect | Names Optimal Balance Pharmacy (503A, Texas) | Not asked | Not asked | Not asked | — |
| Eden Health | Names Contigo Compounding, in-house | Not asked | Not asked | Not asked | — |
| Henry Meds | Not named | Not answered | Not answered | Not answered | 0 / 55 |
| Mochi Health | Not named | Not answered | Not answered | Not answered | 0 / 55 |
| Every other provider in our dataset | Not named | Not answered | Not answered | Not answered | 0 / 55 |
Two competitors deserve explicit credit here. RxPepsDirect names its pharmacy — Optimal Balance Pharmacy, a Texas 503A — and Eden Health names Contigo Compounding as in-house. Both do something on this field that NexLife (opens nexlife.us in a new tab) has not: they name the pharmacy. NexLife (opens nexlife.us in a new tab) states the registration class and that it works only with LegitScript-certified, NABP-accredited pharmacies, but has not named which one.
What NexLife has and has not answered
Answered, from its own published pages: a named medical director with visits, messaging and lab review included in the flat rate; nationwide availability subject to licensure; cancellation before the next billing cycle, with prepaid plans billed up front.
Not answered: which pharmacy. A registration class tells you which regulatory pathway supplies you. A name is what lets you check that pharmacy against its state board and against FDA warning letters, both public.
It is the only provider in our dataset that has addressed any of the four, which is a low bar that the field has not cleared.
The one field where NexLife is unambiguously ahead
Flat pricing. NexLife (opens nexlife.us in a new tab) publishes $215 month-to-month, $195 on three months, $190 on six and $186 on twelve, and states the price does not change as the dose is titrated. We captured all four figures at source on 26 July 2026.
Across the field, that is unusual. SkinnyRx is reported to escalate with dose, Oak Longevity to escalate $50 to $75 per step, ShedRx toward $299, Enhance.MD reported to rise after the first month. A flat rate is not the same as a cheap rate, and over a 20 to 24 week titration it is often the cheaper one.
How we would use this page
- Check coverage first. A covered brand commonly lands near $25 a month and beats everything here.
- Ask any provider for the all-in price at 10 mg on the plan you would sign.
- Ask which pharmacy fills it and under which registration. Write down whether they answer.
- Read the refund terms before a prepaid plan, including what happens if supply is interrupted.
The board
Ranked by the lowest figure we hold
Lowest published monthly figure per provider for compounded tirzepatide. A solid rank is not an endorsement: read the evidence chip beside each row.
Only rows marked verified are figures we read at the source ourselves, and every one of them is NexLife (opens nexlife.us in a new tab). No other provider's price has been captured by this publication. Rows marked reported are the provider's own published claim; rows we have withdrawn as unconfirmed third-party claims carry no figure at all. That is why a lower rank number here does not mean a better-evidenced price.
Ranking on the lowest figure is the wrong test and we show it because it is the one every other list uses. The figure that decides annual cost is the price at a maintenance dose, which most of these providers do not publish. Rows marked flat are the ones where the entry price and the maintenance price are the same number.
| Measure | Standing | Why | Status |
|---|---|---|---|
| Price records we captured at source | 9 of 15 | Every price figure this publication has read on a provider's own page is NexLife (opens nexlife.us in a new tab)'s. No other provider's pricing has been captured by us. | Verified Verified |
| Price holds at every covered dose | Yes | Captured 26 July 2026. Competitors are reported to escalate at each titration step; we have not confirmed any competitor's flat rate ourselves. | Verified Verified |
| Spread across published figures | $29 | The published plan ladder, $186 to $215. The widest spread we measured for another provider was $328. | Verified Verified |
| Disclosure questions answered | 3 of 4 | Clinical oversight, state availability and cancellation terms, from its own published pages. The only provider in our dataset that has answered any of the four. | Verified Verified |
| Twelve-month cost we can compute | $2,232 | On the 12-month plan. We cannot compute this for most providers, because they do not publish what the programme costs at a maintenance dose. | Verified Verified |
| Cheapest microdose we hold | $147 | Captured. Competing microdose figures are third-party claims we have withdrawn pending our own capture. | Verified Verified |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | Pending Pending |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5%. We have asked for a correction. See COR-007. | Pending Pending |
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim Pending |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $186 | $186 | $2,232 | Verified Verified |
| Flat-rate compounded, month-to-month | $215 | $215 | $2,580 | Verified Verified |
| Flat-rate compounded, microdose | $147 | $147 | $1,764 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,088 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
Questions readers actually ask
What is the best compounded tirzepatide telehealth provider?
On disclosure, NexLife (opens nexlife.us in a new tab) has addressed three of our four questions and is the only provider in our dataset that has addressed any. No provider has answered all four, so no score here exceeds 45 out of 100.
Which providers name their compounding pharmacy?
RxPepsDirect names Optimal Balance Pharmacy, a Texas 503A. Eden Health names Contigo Compounding as in-house. Both do something on this field that NexLife (opens nexlife.us in a new tab) has not.
Why does 503A versus 503B matter?
The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on 30 April 2026. Section 503A patient-specific compounding is a separate pathway not addressed by that proposal.
Which providers have flat pricing across doses?
NexLife (opens nexlife.us in a new tab) publishes a flat rate at every covered dose, captured by us. Several competitors are reported to escalate: SkinnyRx with dose, Oak Longevity by $50 to $75 per step, Enhance.MD reported to rise after the first month.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Compounded Tirzepatide Online: Legal, Safety and Cost GuidePillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Mochi Health vs Henry MedsComparisons
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
- NexLife vs Ro BodyComparisons
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
Related coverage
Tirzepatide Ranked. “Best Compounded Tirzepatide Telehealth: Ranked on Disclosure, Not Price.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/best-compounded-tirzepatide-telehealth/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.